Mar 15, 2018 · 53m · y-combinator
Researching Psilocybin's Effects on Depression - Dr. Rosalind Watts · Y Combinator
0:00 / 0:00
▶ Watch on YouTube →
gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions
In this video, clinical psychologist Dr. Rosalind Watts discusses her ground-breaking psilocybin research at Imperial College London, detailing how psychedelic-assisted therapy disrupts severe depression. She highlights the therapeutic mechanisms, the role of compassionate guiding, and the critical necessity of long-term integration and sustainable care frameworks.
How this conversation actually went
Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. How this is scored →
The partners as informed peer 2.1 Guest teaching 5.9 Guest disagreement 0.5 The partners pushing back 0.1
speaking balance: gold is the partners, purple is the guest (3 minute bins)
Sharpest disagreement ▶ 35:45 Critique of directive CBT and therapist ego
Dr. Watts directly criticizes conventional cognitive behavioral therapy and Socratic questioning as overly directive attempts by therapists to force pre-packaged diagnostic formulas onto patients.
Hardest push from the partners ▶ 41:40 Challenging long-term efficacy and relapseCraig presses on the reality that psilocybin's therapeutic benefits frequently fade after a few months, asking how clinicians can realistically set patients up for long-term success.
Biggest teaching moment ▶ 36:25 Unconscious homeostatic intelligence vs therapist diagramsWatts educates the host on how the unconscious mind acts as a self-healing homeostatic system under psilocybin, rendering traditional diagnostic flowcharts and therapist-imposed goals obsolete.
The partners hold their own ▶ 49:15 Synthesizing Pressfield's The War of ArtCraig introduces Steven Pressfield's concept of psychological resistance from The War of Art to frame the universal difficulty of sustaining personal breakthroughs beyond the clinical setting.
the scores for every segment, with the reasoning behind each
| Chapter | Topic | The partners as informed peer | Guest teaching | Guest disagreement | The partners pushing back | Why |
|---|---|---|---|---|---|---|
| Origins of Imperial College Psilocybin Research | 1 | 5 | 0 | 0 | Craig opens with a straightforward question regarding how the research project originated. Dr. Watts provides historical context around Robin Carhart-Harris, David Nutt, and early brain imaging findings on psilocybin deactivating rumination loops. | |
| Historical Context and Revival of Psychedelic Science | 2 | 5 | 0 | 0 | Craig asks whether current trials continue work from the 1960s and how psilocybin is sourced. Watts explains the regulatory hurdles, licensing, and strict GMP synthesis requirements for clinical research. | |
| How Psilocybin Disrupts Depressive Thought Loops | 2 | 6 | 1 | 0 | Craig asks why depression specifically was targeted. Watts details how psilocybin breaks rigid rumination pathways and contrasts the clinical trial's egalitarian therapeutic setting with the constraints and high antidepressant prescription volumes of the NHS. | |
| Preparation and the Low-Dose Experience | 2 | 6 | 0 | 0 | Watts outlines the low-dose 10mg protocol versus the 25mg high dose using the basement metaphor. Craig clarifies whether patients are able to consciously hold onto or suppress their psychological material at differing dosages. | |
| Managing Ego Death and Turbocharged Mindfulness | 2 | 6 | 1 | 0 | Watts describes managing ego death and framing psychedelic therapy as turbocharged mindfulness where patients must surrender rather than resist distress. Craig asks about guide protocols and linguistic preparation. | |
| Patient Backgrounds and the Struggle with Depression | 2 | 6 | 0 | 0 | Craig asks about the patient cohort's background and whether ECT is effective. Watts explains that participants had endured severe treatment-resistant depression for an average of 18 years, having exhausted up to 11 medications. | |
| Antidepressant Withdrawal and Trial Findings | 2 | 7 | 2 | 0 | Craig inquires about the long-term impacts of conventional psychiatric medications. Watts details the severe, often underreported withdrawal symptoms patients experienced when tapering off antidepressants before the trial. | |
| The Three Pillars of Psychedelic Integration | 2 | 6 | 0 | 0 | Watts explains the three pillars of psychedelic therapy—preparation, session, and integration—using the analogy of a snowplow resetting deep sledging tracks in the brain. Craig agrees with the rationale of needing habit reform during the neuroplastic window. | |
| Trial Results and Ethical Funding Dilemmas | 2 | 6 | 1 | 0 | Watts breaks down the specific trial outcomes across the 20 participants and describes the ethical dilemma of seeing depressive symptoms return around the three-month mark without the funding to administer maintenance doses. | |
| Legal Alternatives and International Retreats | 2 | 6 | 0 | 0 | Craig asks what guidance and conversations look like inside the session room. Watts explains that guides act more like loving midwives holding space rather than engaging in directive intellectual dialogue. | |
| Inner Intelligence vs. Directive Talking Therapy | 2 | 7 | 2 | 0 | Watts contrasts traditional CBT's directive Socratic questioning with psilocybin, arguing that the patient's own unconscious mind possesses an innate homeostatic intelligence that outperforms the therapist's diagnostic frameworks. | |
| Designing Long-Term Sustainable Psychedelic Frameworks | 3 | 5 | 0 | 1 | Craig asks how Watts plans to structure future treatment protocols given the recurrence of depression. Watts discusses intermittent lifelong dosing models, integration communities, and contrasts rapid psychedelic shifts with long-term psychoanalysis. | |
| Non-Pharmacological Pathways and Mushroom Connection Metaphor | 3 | 6 | 0 | 0 | Craig brings in Steven Pressfield's concept of resistance from The War of Art to discuss sustaining personal transformation. Watts connects non-pharmacological alternatives like holotropic breathwork and meditation to a wider mycelial network metaphor for human connection. |
Statements from this episode (31)
Watts: David Nutt was fired after stating MDMA is safer than horseriding
“He was, he worked for the government he was the drug czar, so he informed them or advised them about the scientific harms of different drugs and how they should be scheduled or, you know, where they should be in the schedule of illegal drugs, and he was sacked…”
Watts: Psilocybin deactivates brain regions driving negative rumination loops
“And the key finding was that psilocybin seems to deactivate the part of your mind or brain that is responsible for ruminating, for negative thinking on a loop.”
Watts: Imperial College conducted the UK's first psilocybin depression trial
“So they, this, the study that I have, was involved in was a clinical study looking at 20 people with treatment resistant depression, and it was the first study of its kind in the UK”
Watts: Thousands of promising psychedelic studies halted after drugs became illegal
“So in the sixties and seventies, there were, well, in the fifties, sixties and seventies, there were 100,000 of studies. And the findings were really very positive and it would all look great. And then it was, became illegal and then the research just dropped …”
Watts: Sourcing stable psilocybin is a major bottleneck in psychedelic trials
“A lot of the difficulty of doing this research isn't just the bureaucracy cutting through the red tape, getting the licenses, the lack of funding, because the governments obviously don't often want to fund this but it's also actually getting the psilocybin and…”
Watts: Psychedelics can break rigid patterns of thinking and living
“When people are stuck in a very fixed pattern of thinking or of living, psychedelics can break that pattern.”
Watts: Brain imaging shows psychedelics connect normally non-communicating brain regions
“They can provide this state of, when you look at the images of brain communication pathways, they go from this kind of segmented lines to this full on explosion where things that, parts of the brain that don't talk to each other all talk to each other, and sud…”
Watts: Imperial College psilocybin trial tested 10mg and 25mg doses
“In the last study there was a low dose and a high dose session. The low dose session was 10 milligrams, and the high dose was 25, and they look pretty different, these sessions.”
Watts: Psilocybin trials pair each participant with two clinician guides
“So everybody has two guides. They're clinicians, therapists, and they get to know the participant quite well. You have some sessions where you just share about their lives and hear their story, and you tell them a bit about yourself, and it's quite a nice huma…”
Watts: UK reached 64.7 million antidepressant prescriptions last year
“There was 64.7 million prescriptions in the U.K. For antidepressants last year.”
Watts: Antidepressants are short-term fixes ignoring depression's root causes
“You know, as a short-term thing to get people through a crisis time, I think sometimes it can be really helpful, and for some people it works, but for a lot of people it's a short-term fix that doesn't really change the causes of the depression.”
Watts: 10mg psilocybin doses prompt psychodynamic insight while ego stays intact
“On a 10 milligram dose you would see, tend to see more psychodynamic stuff, so internal exploration. People feeling more emotional, feeling that they maybe get some insight into different parts of their life. And often there's struggle because the amount of ps…”
Watts: Patients can resist 10mg psilocybin doses, but 25mg prevents resistance
“With 10 milligrams, it opens it a little bit. And so the things come out and you might be having a conversation with a dead parent, or you might be thinking about a relationship that ended and It's like a very intense turbocharged therapy session, but you can …”
Watts: Psychedelic ego death feels like oneness or physical dying
“When you die on a psychedelic experience, when you have an ego death, that can either feel like, oh, I'm at one with the planet, I am the plants and the trees, I am everything, or it can feel like I'm physically being killed, I'm dying.”
Watts: Psychedelic therapy acts as turbocharged mindfulness
“The whole concept of mindfulness and meditation is about allowing things in and just sitting with them rather than distracting or pushing them away or trying to always be kind of achieving or feeling good, but never feeling your feelings. And it's about that. …”
Watts: Psilocybin trial participants had suffered depression for 18 years on average
“They'd had depression for an average of 18 years, and they tried between I think three and 11 types of antidepressants.”
Watts: Antidepressant research is often short-term to serve drug manufacturers' interests
“The research into the effect of antidepressant drugs often is very short-term. It looks at them for a very short period of time without much follow-up. So because that serves the purposes of the people making these drugs.”
Watts: Antidepressants blunt and essentially stop psilocybin from working
“Psilocybin is not nearly as effective if you're on antidepressants. It really takes the I mean, it takes the highs and the lows. Yeah, yeah, exactly. Yeah. It stops it from working, essentially.”
Watts: Psilocybin's antidepressant effects typically last two to three months
“It seems to, for most people last for about two or three months and then the depression starts to come back.”
Watts: Depression returned after three months without active post-psychedelic integration
“If you just give someone a psychedelic and you don't encourage them to make the most of the window of opportunity, then what we found with our participants is that the depression came back after three months or so.”
Watts: All 20 trial participants preferred psilocybin over previous depression treatments
“So of our 20 well, the first thing to say is that they all said that they would prefer it to any other treatment they tried.”
Watts: Psilocybin trial left 6 of 20 patients depression-free at six months
“So six of them, they were still well after six months. Three of them, it didn't work. And then for 11 of them, and this is, ah, yes, the majority of them, they were really well for three months, depression-free or very mild symptoms of depression. But then aft…”
Watts: Imperial College team will compare psilocybin directly against antidepressants
“So our next study, we're going to be looking at psilocybin versus antidepressants. We're going to be comparing them.”
Watts: Psychedelic therapy guides act like midwives rather than conversational therapists
“You're a bit more like a midwife than a therapist. You know, there's kind of noises and sounds and you're reassuring, but you're not really in an intellectual conversation because getting into the mind is, we want to get out of the mind and into the heart and …”
Watts: Psychedelics quiet frontal ego networks to facilitate somatic emotional processing
“The brilliant thing about psychedelics is that they turn off that kind of ego, frontal parts, and you can go into the body, and into the heart”
Watts: Psilocybin therapy relies on the mind's internal homeostatic healing
“With psilocybin it's completely different because the expert is themselves. They are the expert because what's happening, the healing power of this is something in the unconscious mind, their own unconscious mind is writing itself. There's a homeostatic princi…”
Watts: Demographic therapist matching does not matter in psychedelic therapy
“Beyond that trust, I don't think the coupling, the matching matters because in the session, okay, say, say I've got issues with my mother. It might be that when I go and have talking therapy, I might want to go and see a woman maybe to work through that relati…”
Watts: Psychedelics produce psychoanalysis-level self-understanding rapidly rather than over a decade
“Psychedelics are a bit more like psychoanalysis and that it's learning to understand, understanding yourself much, much better in a very deep way and making changes. And whereas with psychoanalysis it might be a bit more gradual, that people might get to know …”
Watts: Patients are advised against making major decisions post-psilocybin
“We do encourage people after a session not to make any big changes for a couple of weeks. Just to let it sit and percolate and yeah, because people often say, I want to change my job or I want to do this.”